Gastric and enteric involvement in progressive systemic sclerosis

Journal of Clinical Gastroenterology

Volumn 42, Issue 1, 2008, Pages 5-12

  Ebert, Ellen C ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Colon; Diarrhea; Gastric; Malabsorption; Scleroderma; Small intestine

Indexed keywords

CISAPRIDE; ERYTHROMYCIN; METOCLOPRAMIDE; OCTREOTIDE; PRUCALOPRIDE;

ANORECTAL PRESSURE; ANUS SPHINCTER; BACTERIAL OVERGROWTH; BARIUM ENEMA; BLEEDING; BLOATING; FECES INCONTINENCE; FEEDBACK SYSTEM; GASTROINTESTINAL TRACT; HUMAN; INTESTINE DIVERTICULOSIS; INTESTINE PERFORATION; INTESTINE PSEUDOOBSTRUCTION; MALABSORPTION; MANOMETRY; MORBIDITY; MYOELECTRICITY; MYOPATHY; NERVE STIMULATION; NEUROPATHY; PANCREAS INSUFFICIENCY; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; REVIEW; SATIETY; SMALL INTESTINE; STOMACH EMPTYING; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VOMITING;

ANAL CANAL; BIOFEEDBACK (PSYCHOLOGY); COLON; GASTRIC EMPTYING; HUMANS; INTESTINE, SMALL; LUMBOSACRAL PLEXUS; MALABSORPTION SYNDROMES; PEPTIC ULCER PERFORATION; PNEUMATOSIS CYSTOIDES INTESTINALIS; SATIETY RESPONSE; SCLERODERMA, DIFFUSE; STOMACH; STOMACH ULCER; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION; ULCER; VOMITING;

EID: 37549045976     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318042d625     Document Type: Review

References (122)

1. Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol. 2006;40:755-769.
2. Poirier TJ, Rankin GB. Gastrointestinal manifestations of progressive systemic sclerosis based on a review of 364 cases. Am J Gastroenterol. 1972;58:30-44.
3. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin N Am. 1998;27:563-594.
4. Altman RD, Medsger TA, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991;34:403-413.
5. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (Scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428-440.
6. Cohen S, Fisher R, Lipshutz W, et al. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest. 1972;51:2663-2668.
7. DiMarino AJ, Carlson G, Myers A, et al. Duodenal myoelectric activity in scleroderma. Abnormal responses to mechanical and hormonal stimuli. N Engl J Med. 1973;289:1220-1223.
8. Battle WM, Snape WJ, Wright S, et al. Abnormal colonic motility in progressive systemic sclerosis. Ann Intern Med. 1981;94:749-752.
9. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Sem Arthritis Rheum. 1975;4:351-368.
10. Kahaleh MB. Vascular disease in scleroderma: endothelial T-lymphocyte-fibroblast interactions. Rheum Dis Clin North Am. 1990;16:53-73.
11. DeSchryver-Kecskemeti K, Clouse RE. Perineural and intraneural inflammatory infiltrates in the intestines of patients with systemic connective-tissue disease. Arch Pathol Lab Med. 1989;113:394-398.
12. Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology. 2002;123:1144-1150.
13. Howe S, Eaker EY, Sallustio JE, et al. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest. 1994;94:761-770.
14. Eaker E, Kuldau J, Verne GN, et al. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med. 1999;133:551-556.
15. Cavill D, Waterman SA, Gordon TP. Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum. 2003;48:3597-3602.
16. Ibba-Manneschi L, Del Rosso A, Pacini S, et al. Ultrastructural study of the muscle coat of the gastric wall in a case of systemic sclerosis. Ann Rheum Dis. 2002;61:754-756.
17. Marie I, Levesque H, Ducrotte P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001;96:77-83.
18. Fiorucci S, Distrutti E, Gerli R, et al. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol. 1994;89:550-555.
19. Wegener M, Adamek RJ, Wedmann B, et al. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci. 1994;39:2209-2215.
20. Maddern GJ, Horowitz M, Jamieson GG, et al. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology. 1984;87:922-926.
21. Shridhar KR, Lange RC, Magyar L, et al. Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J Lab Clin Med. 1998;132:541-546.
22. Pfaffenbach B, Adamek RJ, Hageman D, et al. Effect of progressive systemic sclerosis on antral myoelectric activity and gastric emptying. Z Gastroenterol. 1996;34:517-521.
23. Franck-Larsson K, Hedenstrom H, Dahl R, et al. Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand J Rheumatol. 2003;32:351-358.
24. Marycz T, Muehldorfer SM, Gruschwitz MS, et al. Gastric involvement in progressive systemic sclerosis: electrogastrographic and sonographic findings. Eur J Gastro Hepatol. 1999;11:1151-1156.
25. Mittal BR, Wanchu A, Das BK, et al. Pattern of gastric emptying in patients with systemic sclerosis. Clin Nucl Med. 1996;21:379-382.
26. Wedmann B, Wegener M, Adamek RJ, et al. Gastrobiliary motility after liquid fatty meal in progressive systemic sclerosis. A Sonographic study. Dig Dis Sci. 1994;39:565-570.
27. Iovino P, Valentini G, Ciacci C, et al. Proximal stomach function in systemic sclerosis. Relationship with autonomic nerve function. Dig Dis Sci. 2001;46:723-730.
28. Bortolotti M, Turba E, Tosti An, et al. Gastric emptying and interdigestive antroduodenal motility in patients with esophageal scleroderma. Am J Gastroenterol. 1991;86:743-747.
29. Marie I, Levesque H, Ducrotte P, et al. Manometry of the upper intestinal tract in patients with systemic sclerosis. Arthritis Rheum. 1998;41:1874-1883.
30. McNearney T, Lin X, Shrestha J, et al. Characterization of gastric myoelectrical rhythms in patients with systemic sclerosis using multichannel surface electrogastrography. Dig Dis Sci. 2002;47:690-698.
31. Pfaffenbach B, Adamek RJ, Hagemann D, et al. Gastric myoelectrical activity and gastric emptying in patients with progressive systemic sclerosis. Am J Gastroenterol. 1996;91:411-412.
32. Johnson DA, Drane WE, Curran J, et al. Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch Intern Med. 1987;147:1597-1601.
33. Rees WDW, Leigh RJ, Christofides ND, et al. Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology. 1982;80:575-580.
34. Horowitz M, Maddern GJ, Maddox A, et al. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology. 1987;93:311-315.
35. Linke R, Meier M, Muenzing W, et al. Prokinetic therapy: what can be measured by gastric scintigraphy? Nucl Med Commun. 2005;26:527-533.
36. Kahan A, Chaussade S, Gaudric M, et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharm. 1991;31:683-687.
37. Dull JS, Raufman J-P, Zakai MD, et al. Successful treatment of gastroparesis with erythromycin in a patient with progressive systemic sclerosis. Am J Med. 1990;89:528-530.
38. Duchini A, Sessoms SL. Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome. Am J Gastroenterol. 1998;93:1453-1456.
39. Rosekrans PC, de Rooy DJ, Bosman FT, et al. Gastrointestinal telangietasia as a cause of severe blood loss in systemic sclerosis. Endoscopy. 1980;12:200-204.
40. Baron M, Srolovitz H. Colonic telangiectasias in a patient with progressive systemic sclerosis. Arthritis Rheum. 1986;29:282-285.
41. Gostout CJ, Viggiano TR, Ahlquist DA, et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol. 1992;15:256-263.
42. Suit PF, Petras RE, Bauer TW, et al. Gastric antral vascular ectasia. A histologic and morphometric study of "The watermelon stomach". Am J Surg Path. 1987;11:750-757.
43. Saverrymuttu SH, Corbishely CM, Maxwell JD, et al. Thickened stomach: an ultrasound sign of portal hypertension. Clin Radiol. 1990;41:17-18.
44. Watson M, Hally RJ, McCue PA, et al. Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. Arthritis Rheum. 1996;39:341-346.
45. Moss SF, Ghosh P, Thomas DM, et al. Gastric antral vascular ectasia: maintenance treatment with oestrogen-progesterone. Gut. 1992;33:715-717.
46. Calam J, Walker RJ. Antral vascular lesion, achlorhydria, and chronic gastrointestinal blood loss. Response to steroids. Dig Dis Sci. 1980;25:236-239.
47. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum. 1994;24:29-39.
48. Bluestone R, MacMahon M, Dawson JM. Systemic sclerosis and small bowel involvement. Gut. 1969;10:185-193.
49. Peachy RDG, Creamer B, Pierce JW. Sclerodermatous involvement of stomach and the small and large bowel. Gut. 1969;10:285-292.
50. Gomez-Puerta JA, Gill V, Cervera R, et al. Coeliac disease associated with systemic sclerosis. Ann Rheum Dis. 2004;63:104-105.
51. Cobden I, Rothwell J, Axon ATR, et al. Small intestinal structure and passive permeability in systemic sclerosis. Gut. 1980;21:293-298.
52. Catanoso M, Lo Gullo R, Giofre MR, et al. Gastro-intestinal permeability is increased in patients with limited systemic sclerosis. Scand J Rheum. 2001;30:77-81.
53. Caserta L, de Magistris L, Secondulfo M, et al. Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheum Int. 2003;23:226-230.
54. Greenberger NJ, Dobbins WO, Ruppert RD, et al. Intestinal atony in progressive systemic sclerosis (scleroderma). Am J Med. 1968;45:301-308.
55. Teh LS, Johns CW, Shaffer JL, et al. Ascorbic acid absorption in patients with systemic sclerosis. J Rheum. 1997;24:2353-2357.
56. Hendel L, Hendel J, Joergensen I. Enterocyte function in progressive systemic sclerosis as estimated by the deconjugation of pteroyltriglutamate to folic acid. Gut. 1987;28:435-438.
57. Ammitzboll T, Hendel L, Kreuzig F, et al. Bioavailability of D-penicillamine in relation to gastrointestinal involvement of generalized scleroderma. Scand J Rheum. 1987;16:121-126.
58. Greydanus MP, Camilleri M. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology. 1989;96:110-115.
59. Sjolund K, Bartosik I, Lindberg G, et al. Small intestinal manometry in patients with systemic sclerosis. Eur J Gastroenterol Hepatol. 2005;17:1205-1212.
60. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461-1467.
61. Akesson A, Ekman R. Gastrointestinal regulatory peptides in systemic sclerosis. Arthritis Rheum. 1993;36:698-703.
62. Horowitz AL, Meyers MA. The "hide-bound"small bowel of scleroderma: characteristic mucosal fold pattern. Am J Roentgenol. 1973;1A:332-334.
63. Cohen S, Laufer I, Snape WJ, et al. The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology. 1980;79:155-166.
64. Krishnamurthy S, Kelly MM, Rohrmann CA, Schuffler MD. Jejunal diverticulosis. A heterogenous disorder caused by a variety of abnormalities of smooth muscle or myenteric plexus. Gastroenterology. 1983;85:538-547.
65. Kaye SA, Lim SG, Taylor M, et al. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheum. 1995;34:265-269.
66. Kaye SA, Siefalian AM, Lim SG, et al. Ischaemia of the small intestine in patients with systemic sclerosis: Raynaud's phenomenon or chronic vasculopathy? Q J Med. 1994;87:495-500.
67. Shindo K, Machida M, Koide K, et al. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepato-Gastroenterol. 1998;45:1643-1650.
68. Stellard F, Sauerbruch T, Luderschmidt CH, et al. Intestinal involvement in progressive systemic sclerosis detected by increased unconjugated serum bile acids. Gut. 1987;28:446-450.
69. Kahn IJ, Jeffries GH, Sleisenger MH. Malabsorption in intestinal scleroderma. Correction by antibiotics. N Engl J Med. 1966;274:1339-1344.
70. Piasecki C, Chin J, Greenslade L, et al. Endoscopic detection of ischaemia with a new probe indicates low oxygenation of gastric epithelium in portal hypertensive gastropathy. Gut. 1995;36:654-656.
71. Quarto Di Palo F, Rivolta R, Berruti V, et al. Superior mesenteric artery blood flow in systemic sclerosis patients. Rheumatol. 2002;41:730-734.
72. Hendel L, Worning H. Exocrine pancreatic function in patients with progressive systemic sclerosis. Scand J Gastroenterol. 1989;24:461-466.
73. Dreiling DA, Soto MJ. The pancreatic involvement in disseminated "collagen" disorders. Studies of pancreatic secretion in patients with scleroderma and Sjogren's "disease". Am J Gastroenterol. 1976;66:546-553.
74. Lundberg AC, Akesson A, Akesson B. Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis. 1992;51:1143-1148.
75. Ng SC, Clements PJ, Berquist WE, et al. Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel disease. Arthritis Rheum. 1989;32:212-216.
76. Govoni M, Muccinelli M, Panicali P, et al. Colon involvement in systemic sclerosis: clinical-radiological correlations. Clin Rheumatol. 1996;15:271-276.
77. Mapp E. Colonic manifestations of the connective tissue disorders. Am J Gastroenterol. 1981;75:386-393.
78. Rohrmann CA, Ricci MT, Krishnamurthy S, et al. Radiologic and histologic differentiation of neuromuscular disorders of the gastrointestinal tract: visceral myopathies, visceral neuropathies, and progressive systemic sclerosis. Am J Radiol. 1981;143:933-941.
79. Martel W, Chang SF, Abell MR. Loss of colonic haustration in progressive systemic sclerosis. Am J Roentgenol. 1976;126:704-713.
80. Plavsic BM, Raider L, Drnovsek VH, et al. Association of rectal diverticula and scleroderma. Acta Radiologica. 1995;36:96-99.
81. Madsen JL, Hendel L. Gastrointestinal transit times of radiolabeled meal in progressive systemic sclerosis. Dig Dis Sci. 1992;37:1404-1408.
82. Whitehead WE, Taitelbaum G, Wigley FM, et al. Rectosigmoid motility and myoelectric activity in progressive systemic sclerosis. Gastroenterology. 1989;96:428-432.
83. Schuffler MD, Rohrmann CA, Chaffee RG, et al. Chronic intestinal pseudo-obstruction. A report of 27 cases and review of the literature. Medicine. 1981;60:173-196.
84. Ortiz-Alvarez O, Cabral D, Prendiville JS, et al. Intestinal pseudoobstruction as an initial presentation of systemic sclerosis in two children. Br J Rheumatol. 1997;36:280-284.
85. Lipton AB, Knauer CM. Pseudo-obstruction of the bowel. Therapeutic trial of metoclopramide. Am J Dig Dis. 1977;22:263-265.
86. Sarna SK, Soergel KH, Koch TR, et al. Gastrointestinal motor effects of erythromycin in humans. Gastroenterology. 1991;101:1488-1496.
87. Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology. 1989;96:704-712.
88. Wang S-J, Lan J-L, Chen D-Y, et al. Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21:271-274.
89. Boeckxstaens GE, Bartelsman JFWM, Lauwers L, et al. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002;97:194-197.
90. Verne GN, Eaker EY, Hardy E, et al. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci. 1995;40:1892-1901.
91. Perlemuter G, Cacoub P, Chaussade S, et al. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum. 1999;42:1545-1549.
92. Norton RA, Monroe LS. The surgical approach to gastrointestinal scleroderma. Report of a case with partial colonic resection. Am J Dig Dis. 1962;7:766-772.
93. Compton R. Scleroderma with diverticulosis and colonic obstruction. Am J Surg. 1969;118:602-606.
94. Jayson JI, Salmon PR, Gough J, et al. Spontaneous bowel perforation in intestinal scleroderma. First report of a non-fatal case. Postgrad Med J. 1972;48:56-58.
95. Davis RP, Hines JR, Flinn WR. Scleroderma of the colon with obstruction: report of a case. Dis Colon Rectum. 1976;19:256-259.
96. Lindsey I, Farmer CR, Cunningham IG. Subtotal colectomy and cecosigmoid anastomosis for colonic systemic sclerosis. Report of a case and review of the literature. Dis Colon Rectum. 2003;46:1706-1711.
97. Stafford-Brady FJ, Kahn HJ, Ross TM, et al. Advanced scleroderma bowel: complications and management. J Rheumatol. 1988;15:869-874.
98. Teoh T-A, Reissman P, Ehrenpreis ED, et al. Colectomy in a constipated scleroderma patient: a word of caution. Am J Gastroenterol. 1995;90:1901-1902.
99. Exadaktylos A, Papagrigoriadis S. Chronic constipation - a lethal danger in patients with systemic scleroderma. Eur J Emergency Med. 2001;8:333-335.
100. Robinson JC, Teitelbaum SL. Stercoral ulceration and perforation of the sclerodermatous colon. Report of two cases and review of the literature. Dis Colon Rectum. 1974;17:622-632.
101. Budd DC, Nirdlinger EL, Sturtz DL, et al. Transverse colon volvulus associated with scleroderma. Am J Surg. 1977;133:370-372.
102. Thompson MA, Summers R. Barium impaction as a complication of gastrointestinal scleroderma. JAMA. 1976;235:1715-1717.
103. Regan PT, Weiland LH, Geall MG. Scleroderma and intestinal perforation. Am J Gastroenterol. 1997;68:566-571.
104. Battle WM, McLean GK, Brooks JJ, et al. Spontaneous perforation of the small intestine due to scleroderma. Dig Dis Sci. 1979;24:80-84.
105. Ebert EC, Ruggiero FM, Seibold JR. Intestinal perforation: a common complication of scleroderma. Dig Dis Sci. 1997;42:549-553.
106. Sequeira W. Pneumatosis cystoids intestinalis in systemic sclerosis and other diseases. Semin Arthritis Rheum. 1990;19:269-277.
107. Miercort RD, Merrill FG. Pneumatosis and pseudo-obstruction in scleroderma. Radiology. 1969;92:359-362.
108. Madura MJ, Craig RM. Duodenal and jejunal diverticula causing a pneumoperitoneum. J Clin Gastroenterol. 1981;3(suppl 1):61-63.
109. Ritchie M, Caravelli J, Shike M. Benign persistent pneumoperitoneum in scleroderma. Dig Dis Sci. 1986;31:552-555.
110. Heyt GJ, Oh MK, Alemzadeh N, et al. Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence. Dig Dis Sci. 2004;49:1040-1045.
111. Engel AF, Kamm MA, Talbot IC. Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence. Gut. 1994;35:857-859.
112. deSouza NM, Williams AD, Wilson HJ, et al. Fecal incontinence in scleroderma: assessment of the anal sphincter with thin-section endoanal MR imaging. Radiology. 1998;208:529-535.
113. Basilisco G, Barbera R, Vanoli M, et al. Anorectal dysfunction and delayed colonic transit in patients with progressive systemic sclerosis. Dig Dis Sci. 1993;38:1525-1529.
114. Chiou A W-H, Lin J-K, Wang F-M. Anorectal abnormalities in progressive systemic sclerosis. Dis Colon Rectum. 1989;32:417-421.
115. Leighton JA, Valdovinos MA, Pemberton JH, et al. Anorectal dysfunction and rectal prolapse in progressive systemic sclerosis. Dis Colon Rectum. 1993;36:182-185.
116. Hamel-Roy J, Devroede G, Arhan P, et al. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology. 1985;88:1-7.
117. Massone C, Milone L, Parodi A, et al. Anorectal involvement is frequent in limited systemic sclerosis. Acta Derm Venereol. 2002;82:446-448.
118. Jaffin BW, Chang P, Spiera H. Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications. J Clin Gastroenterol. 1997;25:513-517.
119. Lock G, Zeuner M, Lang B, et al. Anorectal function in systemic sclerosis. Correlation with esophageal dysfunction? Dis Colon Rectum. 1997;40:1328-1335.
120. Trezza M, Krogh K, Egekvist H, et al. Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol. 1999;34:409-413.
121. Weston S, Thumshirn M, Wiste J, et al. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol. 1998;93:1085-1089.
122. Kenefick NJ, Vaizey CJ, Nicholls RJ, et al. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 2002; 51:881-883.